Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.57 |
| ▸ | MET | P08581 | 2/20 | 0.54 |
| ▸ | ALK | Q9UM73 | 7/20 | 0.51 |
| ▸ | INSR | P06213 | 6/20 | 0.51 |
| ▸ | IGF1R | P08069 | 6/20 | 0.51 |
| ▸ | ROS1 | P08922 | 2/20 | 0.49 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.48 |
| ▸ | PLK4 | O00444 | 1/20 | 0.48 |
| ▸ | STK25 | O00506 | 1/20 | 0.48 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.48 |
| ▸ | CASK | O14936 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | GAK | O14976 | 1/20 | 0.48 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.48 |
| ▸ | MUSK | O15146 | 1/20 | 0.48 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.48 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.48 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26906874 | 0.89 | INSR (0.62) | EGFRMETALKINSRIGF1R | |
| SCHEMBL26906646 | 0.82 | EGFR (0.66) | EGFRMETALKINSRIGF1R | |
| SCHEMBL26906854 | 0.81 | INSR (0.62) | EGFRMETALKINSRIGF1R | |
| SCHEMBL29904634 | 0.81 | ALK (0.63) | EGFRMETALKINSRIGF1R | |
| SCHEMBL26906910 | 0.81 | ALK (0.63) | EGFRMETALKINSRIGF1R | |
| SCHEMBL26906731 | 0.81 | EGFR (0.65) | EGFRMETALKINSRIGF1R | |
| SCHEMBL29904662 | 0.79 | ALK (0.65) | EGFRMETALKINSRIGF1R | |
| SCHEMBL26906710 | 0.79 | ALK (0.65) | EGFRMETALKINSRIGF1R | |
| SCHEMBL26906784 | 0.78 | EGFR (0.59) | EGFRMETALKINSRIGF1R | |
| SCHEMBL26906663 | 0.78 | EGFR (0.57) | EGFRMETALKINSRIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228458-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | THERAPEX CO., LTD. (KR) | 2024-07-11 | — | — | US | claimed |
| EP-4286376-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | Therapex Co., Ltd. (KR) | 2023-12-06 | — | — | EP | claimed |
| US-20240228458-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | THERAPEX CO., LTD. (KR) | 2024-07-11 | — | — | US | disclosed |
| EP-4286376-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | Therapex Co., Ltd. (KR) | 2023-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228458-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | EGFR, ERBB2, ERBB3 | EGFR 1/4885MET 190/4885ALK 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.